Company / Total Assets
CRISPR Therapeutics AG Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$2.3B
FY2025
5-year range
$2.2B / $2.8B
FY2021-FY2025
Trend
+1.0%
vs FY2024
Sector context
#42 of 216
Health Care
What the data says
CRISPR Therapeutics AG's total assets of $2.3B is higher than 81% of companies in the Health Care sector (FY2025). Total Assets has fluctuated over the past 10 years, ranging from $271M in FY2017 to $2.8B in FY2021.
Based on SEC 10-K filings.
$2.3B in FY2025 with a 5-year CAGR of +4.4%. Top quartile in the Health Care sector.
Remained stable around $2.3B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +0.3%
- 5-Year CAGR
- +4.4%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 216This company $2.3B Sector average $7.4B
▼
-69.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.4%, indicating consistent growth.
- In FY2025, total assets increased 1.0% year-over-year.
- Ranks #42 out of 216 companies in the Health Care sector.
- Peak total assets was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.3B | +1.0% |
| FY2024 | $2.2B | +0.6% |
| FY2023 | $2.2B | -0.6% |
| FY2022 | $2.2B | -18.5% |
| FY2021 | $2.8B | +50.5% |
| FY2020 | $1.8B | +71.4% |
| FY2019 | $1.1B | +118.1% |
| FY2018 | $489.0M | +80.2% |
| FY2017 | $271.3M | -21.3% |
| FY2016 | $345.0M | +116.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026